Sharekhan's research report on Torrent Pharmaceuticals
Torrent Pharmaceuticals Limited (Torrent) posted strong revenue growth (after including Curatio’s acquisition). As a result, the company outperformed our revenue estimates. However, the result was in line on the operating front; but performance was far below the expectations on PAT basis. Revenue growth was driven by strong growth across markets. Management has guided that Brazil market will lead growth and Germany should have a steady sequential recovery in the short-medium term. Also, outlook in the US depends on its ability to bring in new products in the market.
We maintain our Buy rating on Torrent Pharma with a revised PT of Rs. 1,788, as we believe while the subdued outlook on the US with two of its facilities being under OAI by the USFDA can restrict robust product launches, strong growth outlook on India market and Brazil expected to outperform the industry growth should drive its earnings at a better trajectory than estimated before.
For all recommendations report, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.